Liraglutide as add‐on to sodium‐glucose co‐transporter‐2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial-Reference-Cited by-同舟云学术

Liraglutide as add‐on to sodium‐glucose co‐transporter‐2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial

Published:2020-02-14 Issue:6 Volume:22 Page:929-937
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Blonde Lawrence¹^ORCID,Belousova Lidia²,Fainberg Udi³,Garcia‐Hernandez Pedro A.⁴,Jain Sunil M.⁵,Kaltoft Margit S.³,Mosenzon Ofri⁶,Nafach Jalal⁷,Palle Mads Sundby³,Rea Rosangela⁸

Affiliation:

1. Ochsner Diabetes Clinical Research Unit, Frank Riddick Diabetes Institute, Department of Endocrinology Ochsner Medical Center New Orleans Louisiana United States

2. Almazov National Medical Research Centre Saint‐Petersburg Russian Federation

3. Novo Nordisk A/S Søborg Denmark

4. Endocrinology Service University Hospital Monterrey Mexico

5. Endocrinology TOTALL Diabetes Hormone Institute Indore Madhya Pradesh India

6. Diabetes Unit, Division of Internal Medicine Hadassah Hebrew University Hospital Jerusalem Israel

7. Dubai Diabetes Center, Dubai Health Authority Dubai United Arab Emirates

8. Endocrinology and Metabolism Service (SEMPR), Universidade Federal do Paraná Curitiba Brazil

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link